NCT03001817已完成3 期
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 551
- 试验地点
- 220
- 主要终点
- Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to understand and willing to comply with all study requirements and procedures throughout the duration of the study and give written informed consent;
- •Aged ≥18 years;
- •Patients receiving moderate- or high-intensity statin therapy must meet one of the following criteria¹ unless they have any exceptional conditions (see inclusion criterion 4):
- •Aged ≥21 years with clinical atherosclerotic cardiovascular disease (ASCVD) (history of acute coronary syndrome or myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack (TIA) presumed to be of atherosclerotic origin, or peripheral arterial disease or revascularization), on a high-intensity statin (or moderate-intensity statin if not a candidate for high-intensity statin due to safety concerns);
- •Aged ≥21 years with a history of LDL-C ≥190 mg/dL, which is not due to secondary modifiable causes, on a high-intensity statin (or moderate-intensity statin if not a candidate for high-intensity statin due to safety concerns);
- •Aged 40 to 75 years, inclusive, without clinical ASCVD but with diabetes and a history of LDL-C of 70 to 189 mg/dL, inclusive, on a moderate- or high-intensity statin; or
- •Aged 40 to 75 years, inclusive, without clinical ASCVD or diabetes, with a history of LDL-C of 70 to 189 mg/dL, inclusive, with estimated 10-year risk for ASCVD of ≥7.5% by the Pooled Cohort Equation on a moderate- or high-intensity statin;
- •Patients currently on a low-intensity statin or not on a statin, must meet one of the following criteria:
- •Patient does not meet any criteria for moderate- or high-intensity statin therapy listed above (see inclusion criteria, criterion 3.a. through 3.d.);
- •Patient does meet one or more criteria for moderate- or high-intensity statin therapy listed above (see inclusion criteria 3.a. through 3.d.); but the patient is not a candidate for moderate or high-intensity statin due to safety concerns, or due to partial or complete statin intolerance; or
- •Patient does meet one or more criteria for moderate- or high intensity statin therapy listed above (see inclusion criteria 3.b. through 3.d., except for 3.a.); but the patient is not a candidate for moderate or high-intensity statin for primary prevention after considering individual risk evaluation (e.g. current LDL C ≤70mg/dL) and patient preference;
排除标准
- •Patients who will require lipid-altering treatments other than study drugs (K-877 or fenofibrate), statins, ezetimibe, or PCSK9 inhibitors during the course of the study. These include bile acid sequestrants, non-study fibrates, niacin (>100 mg/day), omega-3 fatty acids (>1000 mg/day), or any supplements used to alter lipid metabolism including, but not limited to, red rice yeast supplements, garlic supplements, soy isoflavone supplements, sterol/stanol products, or policosanols;
- •Body mass index (BMI) >45 kg/m2 at Visit 1 (Week -8 or Week -6);
- •Patients with type 1 diabetes mellitus;
- •Patients with newly diagnosed (within 3 months prior to Visit 2 [Week -2]) or poorly controlled type 2 diabetes mellitus (T2DM), defined as hemoglobin A1c >9.5% at Visit 1 (Week -8 or Week -6);
研究组 & 干预措施
12 Week Efficacy
Placebo Comparator
K-877 or placebo comparator twice daily for 12 weeks
干预措施: K-877 (Drug)
12 Week Efficacy
Placebo Comparator
K-877 or placebo comparator twice daily for 12 weeks
干预措施: Placebo (for K-877) (Drug)
40 Week Extension
Active Comparator
K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
干预措施: K-877 (Drug)
40 Week Extension
Active Comparator
K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
干预措施: Fenofibrate (Drug)
40 Week Extension
Active Comparator
K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
干预措施: Placebo (for K-877) (Drug)
40 Week Extension
Active Comparator
K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
干预措施: Placebo (for Fenofibrate) (Drug)
结局指标
主要结局
Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12
时间窗: 12 Weeks
次要结局
- Percent Change From Baseline to Week 52 in Apo E(52 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins I(12 Weeks)
- Percent Change From Baseline to Week 52 in FFAs(52 Weeks)
- Percent Change From Baseline to Week 12 in HDL-C(12 Weeks)
- Percent Change From Baseline to Week 12 in Non-HDL-C(12 Weeks)
- Percent Change From Baseline to Week 12 in LDL-C(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo A2(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo B100(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo C2(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Small(12 Weeks)
- Percent Change From Baseline to Week 12 in Remnant Cholesterol(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo B48(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo C3(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo E(12 Weeks)
- Change From Baseline to Week 12 in Fibroblast Growth Factor 21 (FGF21)(12 Weeks)
- Change From Baseline to Week 12 in hsCRP(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Large(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo A1(12 Weeks)
- Percent Change From Baseline to Week 12 in Total Cholesterol(12 Weeks)
- Percent Change From Baseline to Week 12 in Free Fatty Acids (FFAs)(12 Weeks)
- Percent Change From Baseline to Week 12 in Apo B(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Very Low-Density Lipoprotein (VLDL) Cholesterol-Intermediate(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 1(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Intermediate Density Lipoproteins 2(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIb(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIa(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVa(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large(12 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Medium(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles (Total)(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2(12 Weeks)
- Percent Change From Baseline to Week 52 in HDL-C(52 Weeks)
- Percent Change From Baseline to Week 52 in Non-HDL-C(52 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVc(12 Weeks)
- Percent Change From Baseline to Week 52 in Apo A2(52 Weeks)
- Percent Change From Baseline to Week 52 in Apo B(52 Weeks)
- Percent Change From Baseline to Week 52 in Apo B48(52 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIa(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IIIb(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Low Density Lipoproteins IVb(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 3 and 2a(12 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particles-Small(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - Triglyceride (Total)(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of LDL-C:Apo B(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Apo B:Apo A1(12 Weeks)
- Percent Change From Baseline to Week 52 in Fasting TG(52 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - High Density Lipoproteins 2b(12 Weeks)
- Percent Change From Baseline to Week 12 in Ion Mobility - Major LDL Particle Measurement(12 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles (Total)(12 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - Intermediate-density Lipoprotein (IDL) Particles(12 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Large(12 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particles-Small(12 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Large(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Small(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particle Size(12 Weeks)
- Percent Change From Baseline to Week 52 in Remnant Cholesterol(52 Weeks)
- Percent Change From Baseline to Week 52 in Apo A1(52 Weeks)
- Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Particles-Medium(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - LDL Particle Size(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL Particle Size(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipoprotein Fraction - HDL Cholesterol(12 Weeks)
- Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of TG:HDL-C(12 Weeks)
- Percent Change From Baseline to Week 52 in TC(52 Weeks)
- Percent Change From Baseline to Week 52 in LDL-C(52 Weeks)
- Percent Change From Baseline to Week 12 in Lipid and Lipoprotein Ratios of Total Cholesterol (TC):HDL-C(12 Weeks)
- Percent Change From Baseline to Week 52 in Apo B100(52 Weeks)
- Percent Change From Baseline to Week 52 in Apo C2(52 Weeks)
- Percent Change From Baseline to Week 52 in Apo C3(52 Weeks)
- Change From Baseline to Week 52 in FGF21(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Large(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Intermediate(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 1(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins I(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIa(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Large(52 Weeks)
- Change From Baseline to Week 52 in hsCRP(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - VLDL Cholesterol-Small(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Intermediate Density Lipoproteins 2(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIa(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 3 and 2a(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Diameter of the Major LDL Particle(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Medium(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particle Size(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particle Size(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particle Size(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Triglyceride(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TC:HDL-C(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Non-HDL-C:HDL-C(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIb(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IIIb(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVa(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVb(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - High Density Lipoproteins 2b(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL & Chylomicron Particles-Large(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Medium(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - VLDL Particles-Small(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - IDL Particles(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Large(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles-Small(52 Weeks)
- Percent Change From Baseline to Week 52 in Ion Mobility - Low Density Lipoproteins IVc(52 Weeks)
- Change From Baseline to Week 52 in Lipoprotein Fraction - LDL Particles (Total)(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - Triglyceride(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Cholesterol(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of TG:HDL-C(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo C3:Apo C2(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipoprotein Fraction - HDL Particles-Small(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of LDL-C:Apo B(52 Weeks)
- Percent Change From Baseline to Week 52 in Lipid and Lipoprotein Ratios of Apo B:Apo A1(52 Weeks)
研究者
研究点 (220)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal ImpairmentSevere HypertriglyceridemiaNCT03011450Kowa Research Institute, Inc.471
已完成
3 期
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in KoreaModerate to Severe Plaque PsoriasisNCT02982005Kyowa Kirin Korea Co., Ltd.62
已完成
2 期
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833ObesityNCT06019559Kallyope Inc.155
已完成
1 期
Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)HealthyNCT01017458Merck Sharp & Dohme LLC68
撤回
3 期
Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)Skin Structures and Soft Tissue InfectionsNCT00876850Paratek Pharmaceuticals Inc